approval-outlook?agency=FDA+%7C+EMA+%7C+both+%28default%3A+both%29&condition=Disease+area+%E2%80%94+e.g.+%22Alzheimer+Disease%22+%7C+%22Multiple+Myeloma%22+%7C+%22NASH%22+%7C+%22Heart+Failure%22+%7C+%22Obesity%22&horizon=12m+%7C+18m+%7C+24m+%28default%3A+18m%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29

FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results…

FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results, approval-probability scores and historical phase-3 success rates. Worldwide. For biotech-investing and payer agents.

UNRATEDDelisted

Overview

Grade?

UNRATED

0 of 30 paid calls toward a letter

Price

$0.25 per call

Paid calls

none yet

delivery unknown until someone pays

More info

Seller?

0x50ab2018…284912fc

URL

https://clinicalintelpulse.theaslangroupllc.com/api/clinical/approval-outlook?agency=FDA+%7C+EMA+%7C+both+%28default%3A+both%29&condition=Disease+area+%E2%80%94+e.g.+%22Alzheimer+Disease%22+%7C+%22Multiple+Myeloma%22+%7C+%22NASH%22+%7C+%22Heart+Failure%22+%7C+%22Obesity%22&horizon=12m+%7C+18m+%7C+24m+%28default%3A+18m%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29

Seen

first 34 days ago · last 15 days ago

53 free handshakes

Payment

Pays through

x402

Offered on?

algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k, Polygon, eip155:143, eip155:196, Arbitrum, eip155:480, eip155:56, Base USDC, eip155:999, Solana, xrpl:0

Listed on?

Polygon, Arbitrum, Base, Solana

Score, from free handshakes onlyweights 2026.09.5

UN
RATED

0.827 liveness verified, no letter

To a letter · 30 paid calls

0 of 30

Held down by latency p95 · gap to 1.000 is 0.173: 0.082 uncertain ? + 0.091 short ? · 0.073 to A

How the composite of 0.827 is made up, part by part
Component	Weight	Measured	Lower bound ?		Adds	Short ?	Uncertain ?
latency p95costs the most it answered as fast as its class	0.20	0.54	0.513		0.103	−0.091	−0.006
liveness it answered at all	0.60	1.00	0.875		0.525	0	−0.075
price stability the price stayed where it was listed	0.20	1.00	1.000		0.200	0	0
Composite	1.00		0.827	gap to 1.000 = 0.173 · 0.091 short · 0.082 uncertain	0.827	−0.091	−0.082

Not measured: correctness · nobody paid; honesty · nobody paid; schema conformance · no answer had a published shape to check

The multiplication, written out

  0.200 × 0.513   latency p95    
+ 0.600 × 0.875   liveness       
+ 0.200 × 1.000   price stability
= 0.827           → UNRATED: 49 of 30 paid calls      weights 2026.09.5 · 49 samples · seed cap_01M1A51TG1WX3T5NM8FPDHBZEF|2026-08-26T08:30:30.481Z|2026.09.5

Verify it yourself

npx teppi-check https://clinicalintelpulse.theaslangroupllc.com/api/clinical/approval-outlook?agency=FDA+%7C+EMA+%7C+both+%28default%3A+both%29&condition=Disease+area+%E2%80%94+e.g.+%22Alzheimer+Disease%22+%7C+%22Multiple+Myeloma%22+%7C+%22NASH%22+%7C+%22Heart+Failure%22+%7C+%22Obesity%22&horizon=12m+%7C+18m+%7C+24m+%28default%3A+18m%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29

curl -s https://api.teppi.xyz/v1/trust/cap_01M1A51TG1WX3T5NM8FPDHBZEF